company background image

Curaleaf Holdings CNSX:CURA Stock Report

Last Price


Market Cap







28 Jun, 2022


Company Financials +
CURA fundamental analysis
Snowflake Score
Future Growth6/6
Past Performance0/6
Financial Health3/6

CURA Stock Overview

Curaleaf Holdings, Inc. operates a cannabis operator in the United States.


Trading at 94.1% below our estimate of its fair value

Earnings are forecast to grow 74.18% per year

Risk Analysis

No risks detected for CURA from our risk checks.

Curaleaf Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Curaleaf Holdings
Historical stock prices
Current Share PriceCA$6.80
52 Week HighCA$18.19
52 Week LowCA$6.25
1 Month Change-12.26%
3 Month Change-24.61%
1 Year Change-62.20%
3 Year Change-26.72%
5 Year Changen/a
Change since IPO-20.65%

Recent News & Updates

May 20
Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

Here's Why Curaleaf Holdings (CSE:CURA) Has A Meaningful Debt Burden

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Shareholder Returns

CURACA PharmaceuticalsCA Market

Return vs Industry: CURA exceeded the Canadian Pharmaceuticals industry which returned -71% over the past year.

Return vs Market: CURA underperformed the Canadian Market which returned -2.6% over the past year.

Price Volatility

Is CURA's price volatile compared to industry and market?
CURA volatility
CURA Average Weekly Movement7.0%
Pharmaceuticals Industry Average Movement11.7%
Market Average Movement10.0%
10% most volatile stocks in CA Market17.3%
10% least volatile stocks in CA Market4.4%

Stable Share Price: CURA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: CURA's weekly volatility (7%) has been stable over the past year.

About the Company

2010n/aMatt Darin

Curaleaf Holdings, Inc. operates a cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels.

Curaleaf Holdings Fundamentals Summary

How do Curaleaf Holdings's earnings and revenue compare to its market cap?
CURA fundamental statistics
Market CapUS$3.72b
Earnings (TTM)-US$106.90m
Revenue (TTM)US$1.26b


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CURA income statement (TTM)
Cost of RevenueUS$536.60m
Gross ProfitUS$725.82m
Other ExpensesUS$832.72m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date


Earnings per share (EPS)-0.15
Gross Margin57.49%
Net Profit Margin-8.47%
Debt/Equity Ratio32.3%

How did CURA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is CURA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CURA?

Other financial metrics that can be useful for relative valuation.

CURA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue3.5x
Enterprise Value/EBITDA15.2x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CURA's PS Ratio compare to its peers?

CURA PS Ratio vs Peers
The above table shows the PS ratio for CURA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average4.7x
TRUL Trulieve Cannabis
GTII Green Thumb Industries
CL Cresco Labs
CRON Cronos Group
CURA Curaleaf Holdings

Price-To-Sales vs Peers: CURA is good value based on its Price-To-Sales Ratio (3x) compared to the peer average (4.7x).

Price to Earnings Ratio vs Industry

How does CURA's PE Ratio compare vs other companies in the CA Pharmaceuticals Industry?

Price-To-Sales vs Industry: CURA is expensive based on its Price-To-Sales Ratio (3x) compared to the Canadian Pharmaceuticals industry average (1.9x)

Price to Sales Ratio vs Fair Ratio

What is CURA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CURA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3x
Fair PS Ratio3.5x

Price-To-Sales vs Fair Ratio: CURA is good value based on its Price-To-Sales Ratio (3x) compared to the estimated Fair Price-To-Sales Ratio (3.5x).

Share Price vs Fair Value

What is the Fair Price of CURA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CURA (CA$6.8) is trading below our estimate of fair value (CA$115.33)

Significantly Below Fair Value: CURA is trading below fair value by more than 20%.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CURA's PEG Ratio to determine if it is good value.

Discover undervalued companies

Future Growth

How is Curaleaf Holdings forecast to perform in the next 1 to 3 years based on estimates from 19 analysts?

Future Growth Score


Future Growth Score 6/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CURA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.6%).

Earnings vs Market: CURA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CURA is expected to become profitable in the next 3 years.

Revenue vs Market: CURA's revenue (21.3% per year) is forecast to grow faster than the Canadian market (7% per year).

High Growth Revenue: CURA's revenue (21.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: CURA's Return on Equity is forecast to be high in 3 years time (25.1%)

Discover growth companies

Past Performance

How has Curaleaf Holdings performed over the past 5 years?

Past Performance Score


Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: CURA is currently unprofitable.

Growing Profit Margin: CURA is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: CURA is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.

Accelerating Growth: Unable to compare CURA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CURA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (118.1%).

Return on Equity

High ROE: CURA has a negative Return on Equity (-6.43%), as it is currently unprofitable.

Discover strong past performing companies

Financial Health

How is Curaleaf Holdings's financial position?

Financial Health Score


Financial Health Score 3/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: CURA's short term assets ($978.0M) exceed its short term liabilities ($436.8M).

Long Term Liabilities: CURA's short term assets ($978.0M) do not cover its long term liabilities ($1.3B).

Debt to Equity History and Analysis

Debt Level: CURA's net debt to equity ratio (18.9%) is considered satisfactory.

Reducing Debt: CURA's debt to equity ratio has increased from 10.1% to 32.3% over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CURA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CURA has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Discover healthy companies


What is Curaleaf Holdings's current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate CURA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CURA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CURA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CURA's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as CURA has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Matt Darin



Mr. Matthew S. Darin, also known as Matt, served as President of Curaleaf Holdings, Inc since January 04, 2022 until May 09, 2022 and serves as Chief Executive Officer since May 09, 2022. He served as Pres...

Leadership Team

Experienced Management: CURA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Experienced Board: CURA's board of directors are considered experienced (3.7 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Curaleaf Holdings, Inc.'s employee growth, exchange listings and data sources

Key Information

  • Name: Curaleaf Holdings, Inc.
  • Ticker: CURA
  • Exchange: CNSX
  • Founded: 2010
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: CA$4.801b
  • Shares outstanding: 710.14m
  • Website:

Number of Employees


  • Curaleaf Holdings, Inc.
  • 301 Edgewater Place
  • Suite 405
  • Wakefield
  • Massachusetts
  • 1880
  • United States


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Annual Earnings2021/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.